Format

Send to

Choose Destination
See comment in PubMed Commons below
Dermatol Surg. 2006 May;32(5):645-9; discussion 649-50.

Treatment of depression with botulinum toxin A: a case series.

Author information

1
Dermatology and Cosmetic Surgery Associates, Greenbelt, Maryland, USA. efinzi@starpower.net

Abstract

BACKGROUND:

Major depression is a common and serious disease that may be resistant to routine pharmacologic and psychotherapeutic treatment approaches.

OBJECTIVE:

To evaluate the efficacy of botulinum toxin A treatment of glabellar frown lines in treating patients with major depression, using a small open pilot trial.

METHODS:

Patients who met DSM-IV criteria for ongoing major depression in spite of pharmacologic or psychotherapeutic treatment were evaluated with the Beck Depression Inventory II (BDI-II) before receiving botulinum toxin A to their glabellar frown lines. Two months later, all patients were re-evaluated clinically and with the BDI-II.

RESULTS:

Ten depressed patients were treated with botulinum toxin A, and 9 of 10 patients were no longer depressed 2 months after treatment. The tenth patient had an improvement in mood.

CONCLUSION:

To our knowledge, these are the first reported cases of depression treated with botulinum toxin A.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center